AbbVie vs Doceree

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

The U.S. FDA approved AbbVie's JUVMO (tavapadon) on September 28, 2026, as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease. The approval is based on Phase 3 TEMPO data showing significant improvements in daily functioning, increased "on" time without troublesome dyskinesia, and a favorable safety profile. AbbVie expects to make JUVMO available to U.S. patients in October 2026.

• The U.S. FDA approved AbbVie's JUVMO (tavapadon) on September 28, 2026, as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease.
• The approval was supported by Phase 3 TEMPO clinical trial data (TEMPO-1, TEMPO-2, TEMPO-3, and TEMPO-4).
• JUVMO is taken once daily with or without levodopa therapy and is available in 5 mg, 10 mg, and 15 mg tablets plus a Titration Pack containing 0.25 mg and 1 mg tablets.

AbbVie Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued

On September 22, 2026, AbbVie's Executive Vice President, General Counsel and Secretary Perry Siatis testified before the U.S. Trade Representative (USTR) in a Section 301 investigation into Germany. He argued that Germany's pharmaceutical pricing and reimbursement policies undervalue innovation, harm future R&D, and place an unfair cost burden on the U.S. healthcare system. Germany recently increased mandatory manufacturer rebates from 7% to 15.5%, which combined with other measures can reduce a medicine's value by nearly 54%. AbbVie seeks a constructive, fair global agreement on equitable investment in innovation.

• On September 22, 2026, AbbVie's Perry Siatis testified before the USTR in a Section 301 investigation into Germany.
• Germany increased mandatory manufacturer rebates from 7% to 15.5%.
• The cumulative effect of German price controls can reduce an innovative medicine's value by nearly 54%.

Real Time HCP Targeting: How Fast Should Pharma Act on Clinical Intent Signals?

Doceree's article argues that real-time HCP targeting should be measured by signal-to-exposure time, not just data freshness. It outlines four latency stages—signal detection, verified HCP identity, signal-to-activation, and activation-to-exposure—and recommends specific metrics for pharma teams. Doceree's Clinical Intent Signals combine EHR activity, prescribing behavior, and point-of-care context with verified provider identity for NPI-level targeting. Its Intent Powered HCP Suite activates these signals across point of care, programmatic, social, and CTV.

• Doceree defines real-time HCP targeting as the time between a clinical event and the first relevant HCP exposure, not merely signal processing time.
• The clinical signal path includes clinical activity → signal detection → HCP identification → audience activation → ad delivery, with potential latency at each stage.
• Doceree's Clinical Intent Signals use EHR activity, prescribing behavior, point-of-care context, and other decision-moment signals, combined with verified provider identity for NPI-level targeting.

Highlights of the Fierce Pharma Week 2026

On September 14, 2026, Doceree launched its Intent-Powered HCP Suite with a rooftop event and a 300-drone show over Philadelphia, followed by a three-day presence at Fierce Pharma Week 2026. The launch featured the new Daily Command decision layer and extended real-time clinical intent orchestration to CTV, social, and programmatic, alongside existing point-of-care and DOOH channels. During the week, Harshit Jain held a fireside chat with Maria Menounos on clinical intent, and Doceree hosted sessions on agentic AI and reaching all three moments of the prescription journey.

• On September 14, 2026, Doceree hosted a Rooftop Social at Assembly Rooftop Lounge at The Logan Hotel in Philadelphia and launched its Intent-Powered HCP Suite with a 300-drone show over the city.
• The drone show spelled 'Clinical Intent Signals' and 'Understand every intent. Improve every outcome.' above Philadelphia.
• The Intent-Powered HCP Suite extends real-time clinical intent orchestration to CTV, Social, and Programmatic, complementing existing Care Sequence, DOOH, and Point of Care channels.